



Chief Executive: Professor Joe Harrison

Chair: Alison Davis

Request under Freedom of Information Act 2000

Thank you for your request for information which we received on 29 June 2022.

I am pleased to confirm the following.

Over the previous 6 months, how many patients for the following diseases have been treated with a combination of Dabrafenib + Trametinib:

- i) Metastatic Melanoma
- ii) Adjuvant Melanoma
- iii) BRAF mutated Lung Cancer

This combination has not yet been used at MKUH for any indication.

You are advised that this information is provided in accordance with the Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will be subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely.

Freedom of Information Co-ordinator For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the 'Re-use of Public Sector Information Regulations' and best practice.